Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cue Biopharma ( (CUE) ).
On March 26, 2026, Cue Biopharma’s board appointed Chief Financial and Business Officer Lucinda Warren as interim president and chief executive officer, effective March 27, 2026, following the resignation of CEO and director Usman Azam, who stepped down on March 26 and will not stand for re-election at the April 13, 2026 annual stockholders’ meeting. Warren’s amended employment agreement provides a $525,000 annual base salary, a temporary monthly supplement of $10,000 for up to 12 months, eligibility for a target bonus of up to 45% of base salary, and a stock option tied to a financing milestone, while former CEO Azam will receive a lump-sum severance and up to 12 months of company-paid COBRA coverage under his separation agreement, outlining a structured leadership transition with defined financial commitments for both executives.
The most recent analyst rating on (CUE) stock is a Hold with a $0.31 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
The score is primarily held down by persistent losses and negative free cash flow (ongoing financing dependence), partially offset by sharply improved revenue growth, reduced debt, and a financing event that extends runway. Technical signals are mixed/neutral within a longer-term downtrend, and valuation is constrained by negative earnings and no dividend.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma, Inc. operates in the biotechnology and pharmaceutical sector, developing therapeutics that leverage immune modulation for disease treatment. The company focuses on advancing its pipeline through strategic leadership and financial management to strengthen its position in the competitive biopharma market.
Average Trading Volume: 1,592,655
Technical Sentiment Signal: Sell
Current Market Cap: $24.5M
For detailed information about CUE stock, go to TipRanks’ Stock Analysis page.